A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

Phase 1

Completed

• Conditions: Healthy Volunteers
• Interventions: Drug: Placebo; Drug: Psilocybin

• Registration Number: NCT06326606
• Lead Sponsor: MycoMedica Life Sciences PBC

Brief Summary

MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions.

The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy adult participants.

Detailed Description

In recent years, high-dose psilocybin has gained attention for its potential therapeutic benefits in many psychiatric indications, however existing clinical data for low psilocybin doses are limited.

Microdoses are generally considered to be those absent of profound sensory and cognitive effects that would interfere with normal everyday functioning, but only a small number of prospective studies have evaluated microdoses and/or low doses in a controlled manner.

As a foundational study of the therapeutic use of low doses of psilocybin, this study will evaluate the safety, tolerability, pharmacokinetics, and sensorial effects using a prospective, controlled, single ascending dose/multiple ascending doses in healthy volunteers.

Study Timeline

• Study First Submitted: 2024-03-05
• Study First Submitted QC: 2024-03-20
• Study First Posted: 2024-03-22
• Study Start: 2024-03-27
• Primary Completion: 2024-07-08
• Study Completion: 2024-07-08
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-07
• Last Update Posted: 2024-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Males or females aged 18 to 65 years old (inclusive) at the time of signing the informed consent form. Standard contraception measures are required for this clinical trial.
2. Healthy, in the opinion of the Investigator, based on prior (history of) or current (ongoing) medical and psychiatric screening assessments.
3. Participants with no clinically significant findings on physical examination, laboratory tests, and cardiac assessment.
4. Body mass index (BMI) within the range 18-32 kg/m2, inclusive.
5. Normal blood pressure.
6. Capable of giving signed informed consent which includes the requirements and restrictions as per the approved study protocol.

Key

Exclusion Criteria

1. Prior known exposure to psilocybin within the past 10 years.
2. Prior (history of) or current (ongoing) diagnosis, or first-degree relatives with clinically significant medical or psychiatric condition or disease.
3. History of or presence of cardiovascular disease.
4. Abnormal and clinically significant ECG.
5. History or presence of a neurodegenerative disorder such Alzheimer's disease or Parkinson's disease.
6. Use of medications that have CNS effects or affect performance.
7. Use of medications with serotonergic activity.
8. History or presence of hypersensitivity or idiosyncratic reaction to psilocybin or related compounds.
9. History of substance or alcohol abuse disorder in the last 1 year.
10. Participant who, for any reason, is deemed by the Investigator to be inappropriate for this study; or has any condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or is unable to comply with the study protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Active treatment matching capsules will be administered orally as a once a day dose
MLS101	Psilocybin	MLS101 capsule(s) administered orally as a once a day dose

Primary Outcome Measures

Name	Time	Method
Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)	Screening (Day -60) to end of study visit (Day 8)
Occurrence of clinically significant changes in physical examination, vital signs, ECGs, clinical laboratory tests, the Columbia-Suicide Severity Rating Scale (C-SSRS).	Screening (Day -60) to end of study visit (Day 8)	The Columbia Suicide Severity Rating Scale (C-SSRS) is a short questionnaire. If there is a positive result for suicidality on the C-SSRS after Screening (defined by a participant answering "yes" to questions 4 or 5 on the suicidal ideation portion of the C-SSRS), the participant will be evaluated by an Investigator or medically qualified Sub-investigator for continuation in the study. Participants with suicidal ideation or behavior (a "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (Categories 1-10) on the C-SSRS) at any time during the study will be withdrawn from the study. If a participant becomes suicidal during the study, an Investigator or medically qualified Sub-investigator should provide the appropriate treatment to the participant.

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics of MLS101: apparent terminal elimination half-life (t½)	Day 1 to Day 3 post-dose and end of study visit (Day 8)
Cognitive function	Pre-dose (Day -1), Day 1 post-dose and end of study visit (Day 8)	Using validated questionnaires and tools, cognitive function will be assessed and scores will be summarized for each visit, including observed values and change from baseline to evaluate the effects of MLS101 on participants' cognitive function.
Pharmacokinetics of MLS10: area under the plasma concentration-time curve (AUC)	Day 1 to Day 3 post-dose and end of study visit (Day 8)
Pharmacokinetics of MLS101: apparent volume of distribution during the terminal phase (Vz/F)	Day 1 to Day 3 post-dose and end of study visit (Day 8)
Pharmacokinetics of MLS101: apparent total systemic clearance after oral administration (CL/F)	Day 1 to Day 3 post-dose and end of study visit (Day 8)
Pharmacokinetics of MLS101: maximum observed serum concentration (Cmax)	Day 1 to Day 3 post-dose and end of study visit (Day 8)
Pharmacokinetics of MLS101: time corresponding to the occurrence of Cmax (tmax)	Day 1 to Day 3 post-dose and end of study visit (Day 8)
Sensorial effects of MLS101	Day 1 post-dose and end of study visit (Day 8)	Using validated questionnaires, the nominal sensorial threshold dose of MLS101 will be identified. The nominal sensorial threshold dose is defined as the highest dose studied that is absent of clinically significant sensorial effects, and which would not interfere with the participant's ability to carry on with routine activities of daily living. Higher scores indicate presence of sensorial effects.

Trial Locations

Locations (1)

CMAX Clinical Research Pty Ltd; 🇦🇺 Adelaide, South Australia, Australia